Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP) announced that the last patient has completed the first clinical visit in its CANYON-1 Phase 1b clinical trial of CRB-913 for obesity treatment. The company expects to complete the 16-week study by summer 2026.

The CANYON-1 trial is a double-blind, placebo-controlled study involving 240 obese, non-diabetic participants across multiple U.S. clinical sites. The study includes a placebo group and three CRB-913 dose groups of 20 mg, 40 mg, and 60 mg taken orally once daily. All participants receiving CRB-913 start at 20 mg daily and titrate up to their assigned dose level.

CRB-913 is described as a once-daily oral CB1 inverse agonist that is highly peripherally restricted. The drug represents a non-incretin approach to weight management, according to the company.

Earlier Phase 1a study results showed that CRB-913 produced weight loss in obese participants. In the dedicated obese cohort receiving 150 mg daily, all nine CRB-913-treated participants experienced weight loss compared to none in the three-person placebo group. The treated participants achieved a mean 2.9% placebo-adjusted weight loss by day 14.

The Phase 1a study tested doses up to 600 mg daily in single ascending dose trials and up to 150 mg daily in multiple ascending dose trials. The company reported that CRB-913 was well-tolerated across all doses studied, with no reports of vomiting, constipation or nausea. Daily neuropsychiatric assessments were negative.

"Over 40% of those who try incretin therapy turn out to be either intolerant or non-responsive to these drugs," said Yuval Cohen, Chief Executive Officer of Corbus, referring to the discontinuation rate of over 60% for the incretin class of obesity treatments.

Corbus is a clinical-stage company focused on oncology and obesity treatments, headquartered in Norwood, Massachusetts.